000283047 001__ 283047
000283047 005__ 20260112103811.0
000283047 0247_ $$2doi$$a10.1007/s00415-025-13574-3
000283047 0247_ $$2pmid$$apmid:41428120
000283047 0247_ $$2pmc$$apmc:PMC12722382
000283047 0247_ $$2ISSN$$a0367-004X
000283047 0247_ $$2ISSN$$a0012-1037
000283047 0247_ $$2ISSN$$a0340-5354
000283047 0247_ $$2ISSN$$a1432-1459
000283047 037__ $$aDZNE-2025-01454
000283047 041__ $$aEnglish
000283047 082__ $$a610
000283047 1001_ $$aFreri, Fabiola$$b0
000283047 245__ $$aUncovering hypothalamic network disruption in ALS.
000283047 260__ $$a[Darmstadt]$$bSteinkopff$$c2026
000283047 3367_ $$2DRIVER$$aarticle
000283047 3367_ $$2DataCite$$aOutput Types/Journal article
000283047 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768206313_9859
000283047 3367_ $$2BibTeX$$aARTICLE
000283047 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283047 3367_ $$00$$2EndNote$$aJournal Article
000283047 520__ $$aStructural MRI studies have shown hypothalamic atrophy and altered white matter (WM) connectivity in amyotrophic lateral sclerosis (ALS), as a possible substrate of hypermetabolism in this condition. However, hypothalamic functional connectivity and its association with clinical features in ALS remain unclear. This study explored hypothalamic resting-state functional connectivity (RS-FC) in ALS patients compared to controls and its relationship with disease severity defined by the ALS Functional Rating Scale (ALSFRS-r), body mass index (BMI), disease duration, progression rate, survival, hypothalamic volume, and WM integrity.Seventy-one ALS patients and 39 healthy controls underwent structural and RS functional MRI. The bilateral hypothalamus was segmented, and a seed-based RS-FC analysis was performed. Group differences in hypothalamic RS-FC and their correlations with ALSFRS-r scores, BMI, disease duration, progression rate, survival, hypothalamic volume, and WM integrity were assessed. Tract-based spatial statistics was performed to estimate the correlation between WM damage in ALS and hypothalamic RS-FC.ALS patients showed increased hypothalamic RS-FC with caudate nuclei compared to controls. Additionally, greater disease severity correlated with increased hypothalamic RS-FC with the caudate nuclei and orbitofrontal cortex. Hypothalamic RS-FC mean values also associated with FA in the genu of corpus callosum and forceps minor and disease progression rate. No significant correlations were observed with other clinical features.These findings support hypothalamic alterations in ALS. Early detection of hypothalamic changes could be useful in prognostic stratification and evaluating intervention effects.
000283047 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283047 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000283047 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283047 650_7 $$2Other$$aAmyotrophic lateral sclerosis
000283047 650_7 $$2Other$$aFunctional connectivity
000283047 650_7 $$2Other$$aHypermetabolism
000283047 650_7 $$2Other$$aHypothalamus
000283047 650_7 $$2Other$$aMRI
000283047 650_2 $$2MeSH$$aHumans
000283047 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: diagnostic imaging
000283047 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: physiopathology
000283047 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: pathology
000283047 650_2 $$2MeSH$$aFemale
000283047 650_2 $$2MeSH$$aMale
000283047 650_2 $$2MeSH$$aMiddle Aged
000283047 650_2 $$2MeSH$$aHypothalamus: diagnostic imaging
000283047 650_2 $$2MeSH$$aHypothalamus: physiopathology
000283047 650_2 $$2MeSH$$aHypothalamus: pathology
000283047 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000283047 650_2 $$2MeSH$$aAged
000283047 650_2 $$2MeSH$$aAdult
000283047 650_2 $$2MeSH$$aWhite Matter: diagnostic imaging
000283047 650_2 $$2MeSH$$aWhite Matter: pathology
000283047 650_2 $$2MeSH$$aNerve Net: diagnostic imaging
000283047 650_2 $$2MeSH$$aNerve Net: physiopathology
000283047 650_2 $$2MeSH$$aDisease Progression
000283047 650_2 $$2MeSH$$aConnectome
000283047 7001_ $$aSpinelli, Edoardo Gioele$$b1
000283047 7001_ $$aCanu, Elisa$$b2
000283047 7001_ $$aBasaia, Silvia$$b3
000283047 7001_ $$aCastelnovo, Veronica$$b4
000283047 7001_ $$0P:(DE-HGF)0$$aMüller, Hans-Peter$$b5
000283047 7001_ $$0P:(DE-2719)9001967$$aKassubek, Jan$$b6$$udzne
000283047 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b7$$udzne
000283047 7001_ $$aKrishnamurthy, Sruthi Sankari$$b8
000283047 7001_ $$0P:(DE-2719)2812851$$aRoselli, Francesco$$b9$$udzne
000283047 7001_ $$aFilippi, Massimo$$b10
000283047 7001_ $$00000-0003-3121-4979$$aAgosta, Federica$$b11
000283047 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-025-13574-3$$gVol. 273, no. 1, p. 37$$n1$$p37$$tJournal of neurology$$v273$$x0367-004X$$y2026
000283047 8564_ $$uhttps://pub.dzne.de/record/283047/files/DZNE-2025-1454.pdf$$yOpenAccess
000283047 8564_ $$uhttps://pub.dzne.de/record/283047/files/DZNE-2025-1454.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283047 909CO $$ooai:pub.dzne.de:283047$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000283047 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283047 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001967$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283047 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283047 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812851$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000283047 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283047 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000283047 9141_ $$y2025
000283047 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283047 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000283047 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
000283047 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000283047 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283047 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
000283047 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000283047 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x0
000283047 9201_ $$0I:(DE-2719)1910001$$kAG Roselli$$lMetabolic Changes in Neurodegeneration$$x1
000283047 980__ $$ajournal
000283047 980__ $$aVDB
000283047 980__ $$aI:(DE-2719)5000077
000283047 980__ $$aI:(DE-2719)1910001
000283047 980__ $$aUNRESTRICTED
000283047 9801_ $$aFullTexts